Kornimate/medical-research-clean huggingface dataset:
use of an ultra-rapid brca1/2 status screening test in diagnostic and theranostic indication: performance and interest for patients and practitioners

Conditions: Breast Cancer

Summary: the time taken to obtain the results of germline mutations in brca1 and brca2 has become a major issue in adapting the therapeutic management of patients, particularly those with breast cancer. the time taken to obtain the results of brca1/2 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months. the waiting time required to obtain results is likely to cause stress and anxiety in cancer patients. the investigators hypothesise that ultra-rapid testing can reduce anxiety about patients' genetic status and improve their mental well-being. the main objective of this project is to compare the results obtained with an ultra-fast kit developed by o.n.t with those obtained with the current gold standard, ngs sequencing.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * indication for oncogenetic consultation with a wide panel test including brca1/2 (gold standard) as part of the standard theranostic and diagnostic management of breast cancer. * the patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email. * diagnosis of the disease ≤ 6 months * the patient must be affiliated to the social security system. exclusion criteria: * concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires * patients who do not have an email address and/or do not have internet access or tools to connect to the internet * women who are pregnant, may become pregnant or are breast-feeding * persons deprived of their liberty or under guardianship (including curatorship) * inability to undergo trial monitoring for geographical, social or psychological reasons.

Keywords: brca 1/2 breast cancer
applications of realtime functional magnetic resonance imaging (fmri )

Conditions: Pain

Summary: the goal of this research program is to determine the potential effectiveness of real-time fmri training in improving mental control over pain.

a research study that looks at pain and how you experience pain. this research project aims to use virtual reality-based real-time functional magnetic resonance imaging (rtfmri) to assess brain activation during the experience of pain and while subjects attempt to mentally control their pain response.

Eligibility criteria:
inclusion criteria: * age 18-65 * chronic pain patient or healthy control * ability to perform the experimental task exclusion criteria: * mri contraindication (metal implants, claustrophobia, pregnant or planning to become pregnant) * history of psychiatric disorder (at the discretion of the investigator as to whether it interferes with the experimental task) * history of blistering
stage-specific recovery changes in the international classification of functioning components following conservative rehabilitation of trigger finger

Conditions: Trigger Finger

Summary: the aim of this study was to determine the effectiveness of conservative rehabilitation on the multi-dimensional health components based on who icf model in stage 1, stage 2 and stage 3 trigger finger and to determine the functional recovery patterns of each dimension during a three-month rehabilitation period. thirty-four patients were participated in the study.


Eligibility criteria:
inclusion criteria: * diagnosed with stage 1, stage 2 and stage 3 trigger finger based on the froimson classification exclusion criteria: * paediatric trigger finger, trigger thumb, concomitant de'quervain tenosynovitis, carpal tunnel syndrome, or dupuytren's contracture, neurological or rheumatological diseases, chronic pain syndromes, pregnancy and patients with treatment history of related finger/fingers.

Keywords: trigger finger icf rehabilitation splinting
comparative study of tranexamic acid, estrogen for treatment aub in dmpa users

Conditions: Abnormal Uterine Bleeding; Tranexamic Acid; Estrogen; Depot Medroxyprogesterone Acetate

Summary: abnormal uterine bleeding is the most common problems to discontinue depo-medroxyprogesterone acetate (dmpa) in thailand. this clinical trial use to provide drug to stop abnormal uterine bleeding from dmpa

abnormal uterine bleeding is the most common problems to discontinue depo-medroxyprogesterone acetate (dmpa) in thailand. after discontinue dmpa, patients have not used any method. unwanted pregnancy are rising. the reason of abnormal uterine bleeding from dmpa aren't clearly understand. in present, no standard treatment to treat abnormal utrerine bleeding in dmpa users.this clinical trial use to provide drug to stop abnormal uterine bleeding from dmpa with minimal dose and minimal side effect

Eligibility criteria:
inclusion criteria: * abnormal uterine bleeding more than 7 days after first dmpa injection * provide inform consent with patient * can understand thai language exclusion criteria: * have contraindication to use tranexamic acid and estrogen such as hypertension, stroke, mi, dm, renal disease, liver disease, ca breast etc. * have pathology in uterus from pelvic examination, pap smear and ultrasound * current pelvic infection * postpartum less than 6 months * history deep vein thrombosis * breastfeeding

Keywords: aub dmpa tranexamic acid estrogen
effect of a probiotic on visceral fat accumulation

Conditions: Obesity; Intra-Abdominal Fat; Subcutaneous Fat, Abdominal

Summary: the study's main objective is to investigate if an extract containing the probiotic bifidobacterium animalis subsp. lactis bpl1 (cect 8145) has a positive effect on the accumulation of abdominal visceral fat in people with abdominal obesity.

the study's main objective is to investigate if an extract containing the probiotic bifidobacterium animalis subsp. lactis bpl1 (cect 8145) has a positive effect on the accumulation of abdominal visceral fat in people with abdominal obesity. participants: 129 men and women with a waist circumference ≥102 cm (men) or ≥88 cm (women), randomly assigned to one of 3 treatment groups in parallel: one group (43 members) with active probiotic, another one with the probiotic inactivated by heat, and the last group with the placebo. treatment consists of product consumption study for 12 weeks, taking 1 capsule per day. 4 visits during the study, a pre-inclusion visit and 3 study visits (weeks 1, 6, and 12) will be scheduled. secondary objectives are to asses the probiotic's effects on: * the accumulation of subcutaneous body fat and body weight, body mass index (bmi) and waist circumference. * glucose metabolism and insulin resistance. * blood lipid profile. * blood pressure. * inflammation. * circulating levels of adiponectin and leptin. * changes in the intestinal microbiome the statistical analysis will follow the principles specified in the guidelines of the iche9 and cpmp/ewp/908/99 iche9 points to consider on multiplicity issues in clinical trials.

Eligibility criteria:
inclusion criteria: * adults men or women (\>18 years old) * waist circumference ≥102 cm (men) or ≥88 cm (women) and \<150cm * written informed consent provided before the initial screening visit. exclusion criteria: * use of antibiotics within 30-days period before the study * waist circumference other than those specified in inclusion criteria * body mass index (bmi) ≥ 40 kg/m2 * glucose (fasting state) ≥ 126 mg/dl * anemia (hemoglobin ≤13 g/dl in men and ≤12 g/dl in women) * suffer from claustrophobia (to the extent that precludes nmr). * wear pacemakers, electrical stimulators or cochlear implants (nmr contraindications) * following a hypocaloric diet and/or receiving pharmacologic treatment for weight loss * having eating disorders. * use of medication, antioxidant, or multi-vitamin supplements interfering with the study * chronic gastrointestinal pathology * being intolerant or suffer from allergy to any of the products of the study. * pregnant or intending to become pregnant * being in breastfeeding period. * chronic alcoholism * current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study. * failing to follow study guidelines.

Keywords: cardiovascular diseases abdominal visceral fat subcutaneous body fat body weight waist circumference lipid profile insulin resistance glucose metabolism blood pressure inflammation adiponectin leptin metabolomics cardiovascular risk factor
south china prospective cohort study of chronic disease

Conditions: Chronic Disease

Summary: to investigate the risk factors and prediction biomarkers of chronic disease in adults aged 35-74 years.

to investigate the risk factors and prediction biomarkers of chronic disease within adults aged 35-74 years in south china. following up the incidence of major chronic disease including stroke, coronary heart disease, cancer, chronic obstructive pulmonary disease, diabetes and hypertension.

Eligibility criteria:
inclusion criteria: aged 35-74 years local residents or lived in local for 5 years more exclusion criteria: malignancy cognitive impairment that can not cooperate with investigation
effects of incentive spirometry on dyspnea and chest clearance in asthmatic patients during seasonal smog

Conditions: Shortness of Breath

Summary: effects of incentive spirometry on dyspnea and chest clearance in asthmatic patients during seasonal smog

asthma is a serious and life threatening chronic respiratory disease that affects the quality of life of more than 23 million americans- with exposure to air pollution. air pollution can make asthma symptoms worse and trigger asthma attacks. particle pollution can cause breathing problems. it's created when tiny bits of dust, dirt, smoke, soot, and other stuff hang in the air. the smaller the particles, the deeper they can get into the lungs and cause breath problems. seasonal smog aggravates asthma, irritates the lungs, and makes it difficult to breathe. long-term inflammation from breathing in too much ground-level ozone can permanently scar lung tissue. smog with high levels of ozone is also particularly damaging for people with asthma. during seasonal smog asthma patients are more affected than normal people. various consecutive treatments are used to treat the asthma patients for the improvement of quality of life. but at this check the effects of incentive spirometry on dyspnea and chest clearance in asthmatic patients. this study will be randomized controlled trial. this study will be conducted in ittefaq hospital lahore. subjects meeting the predetermined inclusion and exclusion criteria. sample size will be 44 including both male and female. questionnaire used as subjective measurements and ashma control test as objective measurement. dyspnea-12 will be used to check the dyspnea severity in asthma patients and asthma control test will be used to check asthma severity during seasonal smog. cough and sputum assessment questionnaire will be used to check effectiveness of chest clearance. subjects of one group will be treated with active cycle of breathing and incentive spirometry and the other group will be treated with only spirometry. each group will receive 12 treatment sessions with one treatment session per week and it will take less than 1 hour. pre- treatment reading of dynpnea-12, cough and sputum assessment questionnaire and asthma control test will be recorded. and post-treatment readings will also be recorded. outcome variables will be dyspnea-12, incentive spirometry, cough and sputum assessment questionnaire and asthma control test. most commonly used incentive spirometry to clear the dyspnea and chest clearance in asthma patients. data will be analyzed on spss-25.

Eligibility criteria:
inclusion criteria: * age group:30-45 * patients of bronchial asthma * patients who have difficulty in breathing exclusion criteria: * age:\ 45 yrs * patients of copd,bronchiectasis,pneumonia,pulmonary tb or any other chronic lung disease. * patients of htn, ihd, patients of fever or any other chronic disease

Keywords: spirometry,asthma,dyspnea and chest clearance
importance of patient positioning at cough test when considering success following sling procedures

Conditions: Stress Urinary Incontinence

Summary: this is a prospective study to assess the feasibility and success of performing an intra-operative standing cough test and the correlation with the long term success of the sling surgery.

the goal is to seek correlation or disparity between the supine versus the sitting cough test, supine (lying down) versus standing cough test and sitting versus the standing cough test performed at a constant bladder volume; empty in the office and full in the operating room. secondary objective is to test if the intra-operative standing cough test at fullness correlates with long term success of the sling surgery.

Eligibility criteria:
inclusion criteria: * patients who present with stress-dominant urinary incontinence * patients who have undergone a stress test documentation both in the supine and standing/sitting position. * patients who have completed child bearing. * patients between 21 and 89 years of age. exclusion criteria: * patients who do not agree to participate and do not sign the informed consent. * patients undergoing concomitant surgery * patients undergoing surgery under anesthesia.

Keywords: midurethral slings
motor-cognitive training effects on cognition in breast cancer survivors: the brainonfit study (brainonfit).

Conditions: Breast Cancer Survivors; Cognitive Impairment; Executive Dysfunction

Summary: the goal of this interventional study is to assess the effects of either physical exercise program or combined with cognitive training (dual motor and cognitive training program) on breast cancer survivors. the main questions it aims to answer are: * analyze the effectiveness of a supervised dual-task training program or a physical exercise program on the executive functions of the participants. * evaluate the impact of both interventions on physical function, emotional aspects, and important biomarkers related to muscle-brain crosstalk. participants will perform a 20-week supervised and controlled program, three times a week, along with weekly calorie and step challenges. researchers will compare the dual-task training group, with the physical exercise group, and with a control group, which will perform the guideline recommendations of physical activity (non-supervised) to see how these intervention approaches can impact cognitive functions, physical functions, emotional aspects, and biomarkers related to muscle-brain crosstalk. assessments will take place at three-time points: at baseline, after the intervention (20 weeks post-baseline) and after a 12-week follow-up period (32 weeks post-baseline).


Eligibility criteria:
inclusion criteria: * diagnosed with stage i-iiia breast cancer * completed primary treatment, including surgery, radiotherapy and/or chemotherapy * scheduled to receive adjuvant endocrine therapy, or currently receiving adjuvant endocrine therapy * without functional limitations or other illnesses that condition and prevent them from practising intense physical exercise * fact-cog questionnaire score ≥ 10th percentile considering age groups * fluency in spanish (spoken and written) exclusion criteria: * undergoing radiotherapy and/or chemotherapy * fact-cog questionnaire score ≤ 10th percentile considering age groups * congenital heart disease * chronic lung disease * severe psychiatric disorders * history of substance abuse, or dependence (other than tobacco) * mood disorders require treatment (anxiety or depression) * relapses (2-3 months before the study start)

Keywords: cancer-related cognitive impairment physical exercise dual motor-cognitive tasks cognitive stimulation neurocognitive disorders
non-microradical resection margin as a predictor for recurrence after complete mesocolic excision

Conditions: Colon Cancer

Summary: the study aim to investigate the value of the current definition of microradical resection margin in colon cancer. is the distance from tumor tissue to resection margin and the site of any clinically prognostic importance if complete mesocolic excision has been performed.


Eligibility criteria:
inclusion criteria: * undergoing elective curative intended complete mesocolic excision for primary colon adenocarcinoma at nordsjællands hospital in hillerød, denmark * international union against cancer (union internationale contre le cancer - uicc) stage iii - pt1-4, pn1-2 cm0 (gastroepiploic and infrapyloric lymph node metastases are not considered as distant metastases) * resident in denmark at the time of surgery. exclusion criteria: * patients who did not undergo macroradical resections * synchronous colorectal cancer * venous invasion at central venous ligation.
study to assess the effect of formoterol and beclomethasone dipropionate in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the objective of this study is to evaluate the effect of the combination of formoterol and beclometasone dipropionate on central and peripheral airway dimensions in copd patients using computational fluid dynamics (cfd). further more, the effect of this combination therapy on lung function (spirometry, body plethysmography), the bode index, copd assessment test (cat) and borg cr10 scale will be assessed and the safety will be evaluated.


Eligibility criteria:
inclusion criteria: * patients with documented copd based on the following criteria: smoking history of at least 10 pack-years decreased tiffeneau index: fev1/fvc \< 0.70 * male or female patients aged ≥ 40 years * patients should be treated according to the 'global initiative for chronic obstructive lung disease' (gold) guidelines * patients who present * moderate copd with an fev1 between 50 and 80% of predicted gold 2) * severe copd with an fev1 between 30 and 50% of predicted (gold 3) * very severe copd with an fev1 lower than 30% of predicted (gold 4) * patients will be maintained on stable respiratory medications for 6 weeks prior to screening * patients with a co-operative attitude and ability to be trained to correctly use the pmdi * written informed consent obtained exclusion criteria: * pregnant or lactating females or females at risk of pregnancy * unstable patients who developed an exacerbation during the last 4 weeks * inability to carry out pulmonary function testing * diagnosis of asthma as defined by the current 'global initiative for asthma' (gina) guidelines * patients with an uncontrolled disease or any condition that might, in the judgement of the investigator, place the patient at undue risk or potentially compromise the results or interpretation of the study * patients with a qtc interval (bazett's formula) at the screening visit electrocardiogram (ecg) test \>450 msec * cancer or any other chronic disease with poor prognosis and /or affecting patient status * history of alcohol or drug abuse * allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients * patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study * patients who received any investigational new drug within the last 4 weeks prior to the screening visit * patients treated with any non-permitted concomitant medication

Keywords: copd formoterol beclomethasone dipropionate computational fluid dynamics functional imaging central and peripheral airways bode index copd assessment test (cat) borg cr10 scale
study evaluating the safety and effectiveness of etanercept for the treatment of pediatric psoriasis

Conditions: Psoriasis

Summary: psoriasis is a chronic, often severe, autoimmune condition that affects approximately 2% of the world's population. the epidemiology of pediatric psoriasis has not been well documented and no treatment guidelines exist for pediatric psoriasis. etanercept is a biologic drug and has been licensed for the treatment of chronic severe plaque psoriasis in children and adolescents (6-17 years of age) who are inadequately controlled by or are intolerant to, other systemic therapies or phototherapies. although the long-term safety and efficacy of etanercept in children with juvenile idiopathic arthritis (jia) has been studied and the short-term safety profile of etanercept in both jia and pediatric psoriasis appears similar, there is limited data available about the long-term effects of etanercept in pediatric psoriasis, especially with respect to malignancy. the aim of this study is to assess the safety and effectiveness of etanercept for the treatment of pediatric psoriasis in europe. patients aged \<=17 with plaque psoriasis diagnosed by a dermatologist will be invited to participate in the registry only after a clinical decision has been made to prescribe etanercept. the safety of the drug and how well the drug works will be evaluated during the follow-up period. the follow-up period will last 5 years and patients will be followed up every 3 months for the first 2 years and every 6 months for the next 3 years or until the end of study.

non-probability sample

Eligibility criteria:
inclusion criteria: * 17 years of age or younger * diagnosed with plaque psoriasis by a dermatologist. * prior to enrollment, there must be a clinical decision to initiate etanercept for the treatment of plaque psoriasis and etanercept must then be initiated. * actively being treated with etanercept, regardless of length of treatment prior to enrollment * willing to provide written informed consent exclusion criteria: * prior therapy with any biologic agent other than etanercept * history of malignancy

Keywords: pediatric psoriasis etanercept pass safety effectiveness
effects of zolpidem cr® in sleep and heart recovery in cardiac intensive care unit patients

Conditions: Acute Coronary Syndrome; Sleep Deprivation

Summary: a double blind, randomized, placebo-controlled study will be conducted in cardiac icu patients who had been diagnosed with acute coronary syndrome, using a sleep promoting drug (zolpidem controlled release). the study hypothesis is that sleeping better can improve the heart recovery in patients with a diagnosis of acute coronary syndrome.

the environment of an intensive care unit (icu) is notoriously inhospitable to patients who experience a period of sleep deprivation (sd). recent research has shown that sd, even in the short-term, may be related to echo and electrocardiographic changes that may potentially be predictors of cardiac arrhythmias. the objective is to evaluate the effects of early treatment with zolpidem controlled release (cr®) compared to a placebo on clinical and polysomnographic parameters for patients in a cardiac icu who had recently been diagnosed with acute coronary syndrome. a double blind, randomized, placebo-controlled study will be conducted in cardiac icu patients who had been diagnosed with acute coronary syndrome. the patients in group a will receive placebo and patients in group b will receive zolpidem cr® 12.5 mg from the first night of hospitalization until their discharge. patients will undergo overnight full polysomnography on the first night in the icu and will complete a sleep diary with a visual analogue scale to evaluate sleep quality in the morning after the first 3 nights of hospitalization. the results of the routine icu laboratory tests including the serum levels of cardiac enzymes \[troponin t and creatine kinase mb (ck-mb)\] will be collected preceding the first dose of the drug/placebo, and then daily thereafter.

Eligibility criteria:
inclusion criteria: * patients from 18 to 75 years of age * diagnosis of acute coronary syndrome * capable of swallowing pills * capable of filling in the questionaires exclusion criteria: * class iv heart failure according to the new york heart association functional class, * patients in a coma * patients receiving mechanical ventilation * patients who regularly use benzodiazepines or other medications for inducing sleep

Keywords: coronary disease heart diseases enzymes sleep troponin zolpidem